Peptide Briefs

  • The FDA’s Six: What the Human Evidence Actually Shows

    On July 23-24, 2026, something unusual happened at the FDA’s White Oak campus. The Pharmacy Compounding Advisory Committee, a panel that exists to give the agency outside expert advice, voted against FDA staff’s own written recommendations six times in a row. Reporters in the room described an audible gasp when the first tally was read.

    The result: BPC-157, TB-500, Semax, KPV, MOTS-c, and Epitalon all received committee recommendations for inclusion on the FDA’s 503A Bulks List, the mechanism that lets licensed compounding pharmacies legally prepare patient-specific prescriptions. A seventh compound, Emideltide (DSIP), was voted down.

    This is not FDA approval. It’s not even a final decision. It’s a non-binding recommendation, and as of this writing, two months later, the FDA hasn’t acted on it. Formal rulemaking, if it happens, typically takes 8-12 months.

    But the vote raises a question worth answering properly: what does the actual human evidence say about these six compounds? Not the mechanism papers, not the mouse studies people cite as if they settle the matter. The human data specifically. Here’s the honest picture, compound by compound.

    BPC-157

    Grade: D. Plausible mechanism, essentially no human evidence.

    BPC-157 has zero completed human randomized controlled trials. That’s the single fact that matters most here, and it’s worth sitting with before anything else.

    The closest thing to human-scale data is a recent retrospective count of 1,039 documented users, tracked from nadir to follow-up. That’s a real number, but it measures something different than most people assume: it tells you how many people used the compound, not whether it worked. A usage count and an efficacy result are two different questions, and conflating them is the most common error in how this compound gets discussed.

    The clinical history is also more instructive than most coverage lets on. The original research trail goes back to PLIVA, the Croatian pharmaceutical company that worked with discoverer Predrag Sikiric. PLIVA registered early-stage trials around 2000 that were never published. The research was sold to GSX in 2006, and GSX abandoned it. A separate trial in Tijuana in 2015 was also canceled with no data released. Multiple companies with real resources picked this compound up and walked away. That’s a different story than “suppressed because it works,” but it’s also not nothing.

    TB-500

    Grade: D. Same evidence category as BPC-157.

    TB-500 (a synthetic fragment of Thymosin Beta-4) has an extensive preclinical literature on tissue repair, cell migration, and wound healing. None of it has translated into a completed human clinical trial for the injectable research compound as it’s commonly sold.

    The mechanistic story is genuinely interesting; it’s thought to coordinate the movement of cells involved in tissue repair, which is why it shows up so often in sports medicine and regenerative medicine discussions. But “mechanistically interesting” and “shown to work in humans” remain two separate claims, and only the first one currently has support.

    Semax

    Grade: D, with an asterisk worth understanding.

    Semax has a real research history, just not one that shows up cleanly in a PubMed search. A meaningful share of the literature on Semax (and several other Russian-developed compounds, including some of the older bromantane and actovegin research) exists in Russian-language journals that were never translated or indexed in the databases most Western researchers default to.

    This matters because “no human trials” and “no human trials I can find in English” are different claims, and the discourse around Semax tends to treat them as identical. To be direct about the limits of this caveat: this is a well-documented pattern in the space, and it’s a real gap in how evidence gets surfaced, but it isn’t a claim we’ve personally verified paper-by-paper. Treat it as an important qualifier, not a settled fact that resolves the evidence question in Semax’s favor.

    KPV

    Grade: D. The strongest mechanism of the six, and still zero completed human trials.

    KPV is a three-amino-acid fragment of alpha-MSH, and its mechanism is unusually well-characterized for a compound this size. It enters intestinal and immune cells through the PepT1 transporter, the same carrier that handles dipeptides and tripeptides from digested dietary protein, and once inside, it interferes with the importin-alpha3/p65RelA complex, blocking NF-kB nuclear translocation and suppressing downstream inflammatory cytokines (TNF-alpha, IL-1, IL-6).

    The animal data is genuinely strong: DSS and TNBS mouse colitis models (Dalmasso 2008, Kannengiesser 2008) show meaningful reductions in inflammatory markers. The problem is the translation step. DSS/TNBS mouse colitis models have historically translated to human outcomes at only 10-15%, a sobering number for any compound whose entire efficacy case currently rests on mouse data. Zero completed human RCTs exist for KPV in any indication.

    MOTS-c

    Grade: D. The clearest correlation-vs-causation trap of the six.

    MOTS-c is a 16-amino-acid peptide encoded directly in mitochondrial DNA, discovered in 2015. The animal data (primarily mice) shows real effects on insulin sensitivity, inflammatory markers, and glucose homeostasis.

    The human data that exists is purely observational: exercise increases circulating MOTS-c levels in skeletal muscle and blood. That’s a real finding, but it’s a correlation between exercise and a biomarker, not a controlled trial testing whether giving someone exogenous MOTS-c produces a treatment effect. No published human interventional trial has tested that question. The gap between “your body makes more of this when you exercise” and “taking more of this replicates exercise’s benefits” is exactly the kind of gap that’s easy to paper over with hopeful language, and worth naming directly instead.

    Epitalon

    Grade: D. Same literature-access problem as Semax.

    Epitalon carries a near-legendary reputation in longevity circles, and its research history runs into the same issue as Semax: a real body of work exists, much of it Russian in origin, and much of it sits outside what’s easily searchable in English-language databases. The same caveat applies here as it did for Semax: this is a documented pattern worth naming, not a fully verified claim that resolves the evidence gap.

    The pattern across all six

    Every one of these compounds has a plausible, often well-characterized mechanism. Every one has real preclinical (mostly animal) data supporting that mechanism. And every one is missing the thing that actually determines whether a compound works in people: a completed human clinical trial.

    That’s not a condemnation of any of them. Plenty of compounds with this exact profile eventually clear that bar. It’s just the honest state of the evidence right now, and it’s worth being precise about it independent of the regulatory news cycle.

    Here’s the distinction that matters most going forward: a 503A compounding recommendation, if the FDA eventually adopts it, changes the legal pathway for these compounds. It does not change the evidence. Those are two separate axes, and it’s worth not letting a genuinely significant regulatory story get mistaken for a medical one.

    We’ll keep grading these as the literature moves. If any of the six clears a real human trial, that’s the post that follows this one.

  • What a 60%-Off Sale Actually Tells You About a Peptide Supplier

    Troy Snyder, September 2026

    If you’ve spent any time in peptide research circles this month, you’ve seen it: sitewide discounts stacking past 50%, automatic markdowns on top of promo codes, giveaways for anyone who checks out with the right code. One vendor pairs a 45% automatic discount with another 15% off code and calls it “no end date.” Another runs Buy-One-Get-One on top of a percentage code that, stacked correctly, works out to over 60% off per vial.

    It’s tempting to read that as a good deal. It’s worth reading it as a question instead: how does a business built around third-party testing, verified sourcing, and cold-chain shipping sustain a discount that deep, indefinitely, and still stay in business?

    There are really only three ways the math works.

    One: the margin was never that thin to begin with. If a sitewide “sale” price still covers costs at 60% off, the pre-sale price wasn’t reflecting real costs — it was reflecting what the market would bear before the next promo. That’s not illegal. It’s just worth knowing that “sale price” and “fair price” aren’t the same claim.

    Two: something in the process is getting cut to make the discount work. Third-party testing costs money per batch ($200 to $500 per vial depending on the peptide and tests). Verified cold-chain shipping costs money per order. A cryptographically signed Certificate of Analysis, one you can actually verify yourself, not just a PDF with a lab’s letterhead on it costs more than a basic identity check. When the discount is deep enough and permanent enough, ask which of those got quietly thinned out to protect the margin.

    Three: it’s a customer-acquisition strategy, not a pricing strategy. Giveaways, referral drawings, “round two” prize drawings for anyone who already bought these are list-building and retention plays. Nothing wrong with that on its own. But it means the price you’re looking at was never really about the product. It was about winning your business away from whoever you were buying from before, permanently discounted forever, funded by volume rather than margin.

    None of this means every vendor running a deep discount is cutting corners. Some genuinely have better supplier costs and are passing it through, which we are always trying to find and pass on to our customers. That’s the honest version of price competition, and it’s real. The problem is you can’t tell the difference from the discount percentage alone. A 60% off badge tells you nothing about purity. It tells you the marketing team is good at their job.

    So what should you actually check, instead of chasing the number?

    • Is the COA batch-specific, or generic? A Certificate of Analysis tied to the exact lot number on your product is worth infinitely more than a “representative” COA posted once and reused across restocks.
    • Can you verify the signature independently? A cryptographically signed COA (verifiable through the testing lab’s own portal, not just trust-the-PDF) means the document can’t be quietly edited after the fact. Most suppliers don’t offer this because most testing labs don’t offer it standard. It costs more.
    • What method did the testing actually use? UV-Vis identity testing is common and it’s honest as far as it goes, but it can’t distinguish some closely related compounds from each other. HPLC and LC-MS can. If a vendor doesn’t say which method was used, that’s the question to ask before you ask about price.
    • Does the discount depend on you never checking again? The vendors worth trusting are the ones who’d still pass this test at full price. If the pitch only works because you’re excited about the percentage, the pitch is doing the work the product should be doing.

    We built Peptide Briefs on the opposite bet: that researchers would rather know exactly where the evidence stands, including the compounds we grade a C, including the batches that failed identity testing and got discarded rather than shipped, than be sold on a discount that changes weekly. That’s also why every Agape Compounds batch carries a signed, independently verifiable COA rather than a static PDF. We’d rather be the supplier you checked and trusted than the one you almost forgot to check because the price looked good.

    The next time a sitewide discount crosses 50%, don’t ask “how do I stack this.” Ask what it would honestly cost to run this business, then ask why this price doesn’t reflect that.

    — Troy

    Peptide Briefs is an independent research library. We test, grade, and document. We don’t chase the discount war.

  • Behind the Science: How We Verify Every Batch

    “Trust us” isn’t a testing methodology. So here’s exactly what happens before any compound reaches you — not a summary, the actual panel.

    The testing panel

    Every batch goes through independent third-party testing at Purity Analytics, a Georgia-based lab, covering:

    • HPLC (High-Performance Liquid Chromatography) — measures purity, confirming what percentage of the vial is actually the compound it claims to be
    • Mass spectrometry — confirms molecular identity, verifying the compound is what it says it is, not just how pure it is
    • Heavy metals (ICP-MS) — screens for contamination from the manufacturing process
    • TAMC/TYMC — total aerobic microbial count and total yeast/mold count, catching biological contamination
    • Endotoxin testing (LAL) — screens for bacterial endotoxins, especially critical for injectable research compounds

    Why the signature matters more than the number

    A COA is only as trustworthy as its origin. Ours are cryptographically signed using PKCS#7/Sectigo digital signatures — the same underlying technology banks use to verify document authenticity. That means the document itself can prove it hasn’t been altered since the lab issued it, and you can verify that signature yourself in Adobe Acrobat, not just take our description of it on faith.

    Every COA is also independently checkable at verify.purityanalytics.com — you don’t need to trust our website’s claim that testing happened; you can go straight to the lab’s own verification system.

    The honest part

    This process isn’t unique to us, it’s what any legitimate research supplier should be doing. What we think is actually worth pointing out: it’s rare to see suppliers publish the full panel rather than a vague “tested for purity” claim. See our [Research Index] for the published literature these compounds are studied against, and check any batch’s COA yourself before you use it.

    This content is provided for research and informational purposes only. Agape Compounds products are not intended for human or animal consumption.